363 related articles for article (PubMed ID: 34111867)
1. Ruxolitinib for Severe COVID-19-Related Hyperinflammation in Nonresponders to Steroids.
Sarmiento M; Rojas P; Jerez J; Bertín P; Campbell J; García MJ; Pereira J; Triantafilo N; Ocqueteau M
Acta Haematol; 2021; 144(6):620-626. PubMed ID: 34111867
[TBL] [Abstract][Full Text] [Related]
2. Compassionate use of ruxolitinib in patients with SARS-Cov-2 infection not on mechanical ventilation: Short-term effects on inflammation and ventilation.
Mortara A; Mazzetti S; Margonato D; Delfino P; Bersano C; Catagnano F; Lauriola M; Grosso P; Perseghin G; Ippoliti G
Clin Transl Sci; 2021 May; 14(3):1062-1068. PubMed ID: 33403775
[TBL] [Abstract][Full Text] [Related]
3. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.
La Rosée F; Bremer HC; Gehrke I; Kehr A; Hochhaus A; Birndt S; Fellhauer M; Henkes M; Kumle B; Russo SG; La Rosée P
Leukemia; 2020 Jul; 34(7):1805-1815. PubMed ID: 32518419
[TBL] [Abstract][Full Text] [Related]
4. The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS).
Neubauer A; Johow J; Mack E; Burchert A; Meyn D; Kadlubiec A; Torje I; Wulf H; Vogelmeier CF; Hoyer J; Skevaki C; Muellenbach RM; Keller C; Schade-Brittinger C; Rolfes C; Wiesmann T
Leukemia; 2021 Oct; 35(10):2917-2923. PubMed ID: 34385593
[TBL] [Abstract][Full Text] [Related]
5. JAK/STAT Pathway Inhibition May Be a Promising Therapy for COVID-19-Related Hyperinflammation in Hematologic Patients.
Rojas P; Sarmiento M
Acta Haematol; 2021; 144(3):314-318. PubMed ID: 32726783
[TBL] [Abstract][Full Text] [Related]
6. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial.
Cao Y; Wei J; Zou L; Jiang T; Wang G; Chen L; Huang L; Meng F; Huang L; Wang N; Zhou X; Luo H; Mao Z; Chen X; Xie J; Liu J; Cheng H; Zhao J; Huang G; Wang W; Zhou J
J Allergy Clin Immunol; 2020 Jul; 146(1):137-146.e3. PubMed ID: 32470486
[TBL] [Abstract][Full Text] [Related]
7. Favorable COVID-19 course despite significant comorbidities in a ruxolitinib-treated patient with primary myelofibrosis.
Koschmieder S; Jost E; Cornelissen C; Müller T; Schulze-Hagen M; Bickenbach J; Marx G; Kleines M; Marx N; Brümmendorf TH; Dreher M
Eur J Haematol; 2020 Nov; 105(5):655-658. PubMed ID: 32593209
[TBL] [Abstract][Full Text] [Related]
8. Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study.
Vannucchi AM; Sordi B; Morettini A; Nozzoli C; Poggesi L; Pieralli F; Bartoloni A; Atanasio A; Miselli F; Paoli C; Loscocco GG; Fanelli A; Para O; Berni A; Tassinari I; Zammarchi L; Maggi L; Mazzoni A; Scotti V; Falchetti G; Malandrino D; Luise F; Millotti G; Bencini S; Capone M; Piccinni MP; Annunziato F; Guglielmelli P;
Leukemia; 2021 Apr; 35(4):1121-1133. PubMed ID: 32814839
[TBL] [Abstract][Full Text] [Related]
9. Ruxolitinib versus dexamethasone in hospitalized adults with COVID-19: multicenter matched cohort study.
Stanevich OV; Fomina DS; Bakulin IG; Galeev SI; Bakin EA; Belash VA; Kulikov AN; Lebedeva AA; Lioznov DA; Polushin YS; Shlyk IV; Vorobyev EA; Vorobyeva SV; Surovceva TV; Bakulina NV; Lysenko MA; Moiseev IS
BMC Infect Dis; 2021 Dec; 21(1):1277. PubMed ID: 34937556
[TBL] [Abstract][Full Text] [Related]
10. Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia.
D'Alessio A; Del Poggio P; Bracchi F; Cesana G; Sertori N; Di Mauro D; Fargnoli A; Motta M; Giussani C; Moro P; Vitale G; Giacomini M; Borra G
Leukemia; 2021 Feb; 35(2):635-638. PubMed ID: 33173161
[No Abstract] [Full Text] [Related]
11. Ruxolitinib as a treatment strategy for SARS-CoV-2 pneumonia: clinical experience in a real-world setting.
Ovilla-Martinez R; Cota-Rangel X; De La Peña-Celaya J; Alvarado-Zepeda MA; Jiménez Sastré A; Azuara Forcelledo H; Ordoñez Rodriguez B; Pulido Broca J; Molina Jaimes A; Muñiz-Carvajal A; Bahena García MM; Cervera Ceballos E; Zapata Canto NP; García Mendez JO; García Jímenez ON; Salas Heredia JA; Solis Soto J; Villalobos Mendez RA; Ignacio Ibarra G; Ledesma de la Cruz C; Araujo Martinez N; Juárez Lara J; Ceballos Zuñiga CO; Villaseñor Pérez FV; Herrera Garcia JC; Nuche Salazar P; Dominguez Paregrina A; Arizpe Bravo B; Enciso Figueroa G; Trujillo T; Miguel Álvarez A; García Gallegos DJ; Ortiz Arroyo A; Solorzano Soto CI; Jaramillo Ramírez HJ; De la Cruz Hernández I; De Gante Martínez S; Montesinos Gómez GE; Martínez Velasco S; García Graullera R; Vázquez López MA; Urbalejo Ceniceros VI; Lugo García Y; González Ávila AI; Duque Rodriguez J; Ruiz Luján R; Rodríguez Rivera VI; Soberanes Ramírez L; Baez-Islas PE
J Infect Dev Ctries; 2022 Jan; 16(1):63-72. PubMed ID: 35192523
[TBL] [Abstract][Full Text] [Related]
12. [Proactive anti-inflammatory and anticoagulant therapy in the treatment of advanced stages of novel coronavirus infection (COVID-19). Case Series and Study Design: COLchicine versus ruxolitinib and secukinumab in open prospective randomIzed trial (COLORIT)].
Mareev VY; Orlova YA; Pavlikova EP; Akopyan ZA; Matskeplishvili ST; Plisyk AG; Seredenina EM; Potapenko AV; Malakhov PS; Samokhodskaya LM; Mershina ЕА; Sinitsyn VE; Asratyan DA; Zhdanova EA; Mareev YV; Begrambekova YL; Shatochina EA; Kamalov АА
Kardiologiia; 2020 Oct; 60(9):4-21. PubMed ID: 33131470
[TBL] [Abstract][Full Text] [Related]
13. Ruxolitinib in the management of steroid-resistant/-dependent acute and chronic graft-versus-host disease: results of routine practice in an academic centre.
Leung GMK; Sim JPY; Hwang YY; Chan TSY; Lie AKW; Tse E; Kwong YL
Ann Hematol; 2022 Jan; 101(1):155-163. PubMed ID: 34767056
[TBL] [Abstract][Full Text] [Related]
14. Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation.
Heidel F; Hochhaus A
Leukemia; 2020 Jul; 34(7):1723-1725. PubMed ID: 32528040
[No Abstract] [Full Text] [Related]
15. Severe COVID-19 in a patient with chronic graft-versus-host disease after hematopoietic stem cell transplant successfully treated with ruxolitinib.
Saraceni F; Scortechini I; Mancini G; Mariani M; Federici I; Gaetani M; Barbatelli P; Minnucci ML; Bagnarelli P; Olivieri A
Transpl Infect Dis; 2021 Feb; 23(1):e13401. PubMed ID: 32629531
[TBL] [Abstract][Full Text] [Related]
16. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
Harrison CN; Vannucchi AM; Platzbecker U; Cervantes F; Gupta V; Lavie D; Passamonti F; Winton EF; Dong H; Kawashima J; Maltzman JD; Kiladjian JJ; Verstovsek S
Lancet Haematol; 2018 Feb; 5(2):e73-e81. PubMed ID: 29275119
[TBL] [Abstract][Full Text] [Related]
17. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
[TBL] [Abstract][Full Text] [Related]
18. Randomized Phase 3 Trial of Ruxolitinib for COVID-19-Associated Acute Respiratory Distress Syndrome.
Rein L; Calero K; Shah R; Ojielo C; Hudock KM; Lodhi S; Sadaka F; Bellam S; Palma C; Hager DN; Daniel J; Schaub R; O'Hayer K; Theodoropoulos NM
Crit Care Med; 2022 Dec; 50(12):1701-1713. PubMed ID: 36226977
[TBL] [Abstract][Full Text] [Related]
19. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
Stratton CW; Tang YW; Lu H
J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
[TBL] [Abstract][Full Text] [Related]
20. Iatrogenic Kaposi's sarcoma in a myelofibrosis patient treated with ruxolitinib: Case-report, literature review, and French pharmacovigilance data.
Moutel M; Noel V; Jary A; Le QH; Lier C; Viguier M; Lebbe C; Azzouz B; Bani-Sadr F
Am J Hematol; 2022 Jan; 97(1):E31-E34. PubMed ID: 34724250
[No Abstract] [Full Text] [Related]
[Next] [New Search]
